| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
From the Neuroendocrinologie et Biologie Cellulaire Digestives, INSERM U410, Institut National de la Santé et de la Recherche Médicale, Paris, France
The traditional view on the role of serine proteases in tumor biology has changed with the recent discovery of a family of protease-activated receptors (PARs). In this study we explored the expression and functional role of the thrombin receptor PAR-1 in human colon cancer cells. Reverse transcriptase-polymerase chain reaction analysis showed that PAR-1 mRNAs are present in 11 of 14 human colon cancer cell lines tested but not in normal human colonic epithelial cells. This is in line with the immunolocalization of PAR-1 in human colon tumors and its absence in normal human colonic mucosa. The functional significance of the aberrant expression of PAR-1 in colon cancer cells was then investigated. We found that 1) a prompt increase in intracellular calcium concentration was observed on thrombin (10 nmol/L) or PAR-1 agonist AP1 (100 µmol/L) challenge of HT29 cells; 2) HT29 quiescent cells treated with thrombin (0.01 to 20 nmol/L) or AP1 (1 to 300 µmol/L) exhibited dramatic mitogenic responses (3.5-fold increase in cell number). Proliferative effects of thrombin or AP1 were also observed in other colon cancer cell lines expressing PAR-1. This effect was reversed by the MEK inhibitor PD98059 in consonance with the ability of thrombin or AP1 to induce phosphorylation of p42/p44 extracellular-regulated protein kinases. 3) PAR-1 activation by thrombin or AP1 led to a two-fold increase in cell motility of wounded HT29-D4. Our results demonstrate for the first time the aberrant expression of the functional thrombin receptor PAR-1 in colon cancers and its important involvement in cell proliferation and motility. Thrombin should now be considered as a growth factor for human colon cancer.
This article has been cited by other articles:
 |
|
 |
|
  S. G. I. Suliman, A. Gurlek, J. V. Byrne, N. Sullivan, G. Thanabalasingham, S. Cudlip, O. Ansorge, and J. A. H. Wass Nonsurgical Cerebrospinal Fluid Rhinorrhea in Invasive Macroprolactinoma: Incidence, Radiological, and Clinicopathological Features J. Clin. Endocrinol. Metab., October 1, 2007; 92(10): 3829 - 3835. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 I Jahan, J Fujimoto, S. M. Alam, E Sato, H Sakaguchi, and T Tamaya Role of protease activated receptor-2 in tumor advancement of ovarian cancers Ann. Onc., September 1, 2007; 18(9): 1506 - 1512. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. C Moss, P. Anton, T. Savidge, P. Newman, A. S Cheifetz, J. Gay, S. Paraschos, M. W. Winter, M. P Moyer, K. Karalis, et al. Urocortin II mediates pro-inflammatory effects in human colonocytes via corticotropin-releasing hormone receptor 2{alpha} Gut, September 1, 2007; 56(9): 1210 - 1217. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. Arora, T. K. Ricks, and J. Trejo Protease-activated receptor signalling, endocytic sorting and dysregulation in cancer J. Cell Sci., March 15, 2007; 120(6): 921 - 928. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. Cao, N. Dronadula, F. Rizvi, Q. Li, K. Srivastava, W. T. Gerthoffer, and G. N. Rao Novel Role for STAT-5B in the Regulation of Hsp27-FGF-2 Axis Facilitating Thrombin-Induced Vascular Smooth Muscle Cell Growth and Motility Circ. Res., April 14, 2006; 98(7): 913 - 922. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. Cao, N. Dronadula, and G. N. Rao Thrombin induces expression of FGF-2 via activation of PI3K-Akt-Fra-1 signaling axis leading to DNA synthesis and motility in vascular smooth muscle cells Am J Physiol Cell Physiol, January 1, 2006; 290(1): C172 - C182. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. I. W. Osmond, A. Sheehan, R. Borowicz, E. Barnett, G. Harvey, C. Turner, A. Brown, M. F. Crouch, and A. R. Dyer GPCR Screening via ERK 1/2: A Novel Platform for Screening G Protein-Coupled Receptors J Biomol Screen, October 1, 2005; 10(7): 730 - 737. [Abstract] [PDF]
|
|
|
|
|
|
N Vergnolle CLINICAL RELEVANCE OF PROTEINASE ACTIVATED RECEPTORS (PARS) IN THE GUT Gut, June 1, 2005; 54(6): 867 - 874. [Full Text] [PDF]
|
|
|
|
|
|
Y. Hirota, Y. Osuga, T. Hirata, O. Yoshino, K. Koga, M. Harada, C. Morimoto, E. Nose, T. Yano, O. Tsutsumi, et al. Possible Involvement of Thrombin/Protease-Activated Receptor 1 System in the Pathogenesis of Endometriosis J. Clin. Endocrinol. Metab., June 1, 2005; 90(6): 3673 - 3679. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. James, D. J. Collison, and G. Duncan Characterization and Functional Activity of Thrombin Receptors in the Human Lens Invest. Ophthalmol. Vis. Sci., March 1, 2005; 46(3): 925 - 932. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Steinhoff, J. Buddenkotte, V. Shpacovitch, A. Rattenholl, C. Moormann, N. Vergnolle, T. A. Luger, and M. D. Hollenberg Proteinase-Activated Receptors: Transducers of Proteinase-Mediated Signaling in Inflammation and Immune Response Endocr. Rev., February 1, 2005; 26(1): 1 - 43. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. Dronadula, Z. Liu, C. Wang, H. Cao, and G. N. Rao STAT-3-dependent Cytosolic Phospholipase A2 Expression Is Required for Thrombin-induced Vascular Smooth Muscle Cell Motility J. Biol. Chem., January 28, 2005; 280(4): 3112 - 3120. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Z. Salah, M. Maoz, I. Cohen, G. Pizov, D. Pode, M. S. Runge, and R. Bar-Shavit Identification of a novel functional androgen response element within hPar1 promoter: implications to prostate cancer progression FASEB J, January 1, 2005; 19(1): 62 - 72. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. V. M. Rao and U. R. Pendurthi Tissue Factor-Factor VIIa Signaling Arterioscler. Thromb. Vasc. Biol., January 1, 2005; 25(1): 47 - 56. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 X. Zhang, J. L. Hunt, D. P. Landsittel, S. Muller, K. Adler-Storthz, R. L. Ferris, D. M. Shin, and Z.(G. Chen Correlation of Protease-Activated Receptor-1 With Differentiation Markers in Squamous Cell Carcinoma of the Head and Neck and Its Implication in Lymph Node Metastasis Clin. Cancer Res., December 15, 2004; 10(24): 8451 - 8459. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. Rouet-Benzineb, C. Rouyer-Fessard, A. Jarry, V. Avondo, C. Pouzet, M. Yanagisawa, C. Laboisse, M. Laburthe, and T. Voisin Orexins Acting at Native OX1 Receptor in Colon Cancer and Neuroblastoma Cells or at Recombinant OX1 Receptor Suppress Cell Growth by Inducing Apoptosis J. Biol. Chem., October 29, 2004; 279(44): 45875 - 45886. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. Darmoul, V. Gratio, H. Devaud, F. Peiretti, and M. Laburthe Activation of Proteinase-Activated Receptor 1 Promotes Human Colon Cancer Cell Proliferation Through Epidermal Growth Factor Receptor Transactivation Mol. Cancer Res., September 1, 2004; 2(9): 514 - 522. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
X. Shi, B. Gangadharan, L. F. Brass, W. Ruf, and B. M. Mueller Protease-Activated Receptors (PAR1 and PAR2) Contribute to Tumor Cell Motility and Metastasis Mol. Cancer Res., July 1, 2004; 2(7): 395 - 402. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Jarry, L. Charrier, C. Bou-Hanna, M.-C. Devilder, V. Crussaire, M. G. Denis, G. Vallette, and C. L. Laboisse Position in Cell Cycle Controls the Sensitivity of Colon Cancer Cells to Nitric Oxide-Dependent Programmed Cell Death Cancer Res., June 15, 2004; 64(12): 4227 - 4234. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. Darmoul, V. Gratio, H. Devaud, and M. Laburthe Protease-activated Receptor 2 in Colon Cancer: TRYPSIN-INDUCED MAPK PHOSPHORYLATION AND CELL PROLIFERATION ARE MEDIATED BY EPIDERMAL GROWTH FACTOR RECEPTOR TRANSACTIVATION J. Biol. Chem., May 14, 2004; 279(20): 20927 - 20934. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 V. S. OSSOVSKAYA and N. W. BUNNETT Protease-Activated Receptors: Contribution to Physiology and Disease Physiol Rev, April 1, 2004; 84(2): 579 - 621. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
